Odanacatib, An Investigational Cathepsin K Inhibitor, Reduced Markers Of Bone Turnover In Women With Breast Cancer And ... (Medical News Today)
Merck & Co., Inc, Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme or MSD, announced results of a new study in which its investigational selective cathepsin K inhibitor odanacatib reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast cancer that has spread to the bones (bone metastases).
Strontium and osteoporosis: A treatment not offered to American women (Online Journal)
The purpose of this article is to provide a summary of current published research on the mineral strontium and its purported function in preventing osteoporotic fractures in postmenopausal women.
Bone and Cancer Foundation Funds Critical Research on Fighting the Spread of Cancer (PRWeb via Yahoo! News)
The first Noa Schwartz Siris Research Grant has been awarded to Pierrick G. Fournier, PhD an Instructor at the University of Virginia, for his research on bone metastasis. The award is named in memory of Noa Schwartz Siris, a physician who died of osteosarcoma at the age of 29. The award is managed by the Bone and Cancer Foundation, a project of the Paget Foundation, in New York City.
Odanacatib, an Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and ... (Business Wire via Yahoo! Finance)
EDINBURGH, Scotland----Merck & Co., Inc, Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme or MSD, announced results of a new study in which its investigational selective cathepsin K inhibitor odanacatib reduced measures of bone turnover in women with breast cancer that has spread to the bones .
Cells in blood may help cancers spread (Reuters via Yahoo! News)
Normal cells in the blood that play a role in healing wounds may also be creating the right conditions for cancer cells to spread, U.S. researchers said on Tuesday.
